Atropos Therapeutics

Atropos Therapeutics is a private, preclinical-stage biotech leveraging a novel understanding of cellular senescence to develop first-in-class therapeutics. The company's core innovation is the FATES platform, a phenotypic screening technology based on the detection of ATRX foci, which aims to identify 'senosuppressors' to prevent harmful senescence in aging and 'senostimulators' to induce beneficial senescence in cancer. With a seasoned leadership team and scientific advisory board, Atropos is positioned in the rapidly growing longevity and senotherapeutics space, though it faces significant technical and competitive risks inherent to pioneering a new drug discovery approach.

FATES (First ATRX-based Therapeutics to Elucidate Senescence) - a patent-pending, cell-based phenotypic screening platform that detects de novo ATRX foci to identify small molecules that modulate the formation of senescent cells via the SAGA (Senescence After Growth Arrest) pathway.

Atropos competes in the senotherapeutics space against companies developing senolytic drugs (e.g., Unity Biotechnology) and other aging-targeted mechanisms (e.g., NAD+ boosters). Its key differentiation is its focus on modulating the *formation* of senescent cells via the SAGA pathway, rather than eliminating existing senescent cells, which it posits could offer greater selectivity.